[1
]
QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
[2
]
Quantitative Biosciences Institute (QBI), University of California San Francisco,
San Francisco, CA, USA.
[3
]
J. David Gladstone Institutes, San Francisco, CA, USA.
[4
]
Department of Cellular and Molecular Pharmacology, University of California San Francisco,
San Francisco, CA, USA.
[5
]
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY,
USA.
[6
]
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount
Sinai, New York, NY, USA.
[7
]
Department of Computational Medicine and Bioinformatics, University of Michigan, Ann
Arbor, MI, USA.
[8
]
Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
[9
]
Department of Pharmaceutical Chemistry, University of California San Francisco, San
Francisco, CA, USA.
[10
]
Howard Hughes Medical Institute, University of California San Francisco, San Francisco,
CA, USA.
[11
]
European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome
Genome Campus, Cambridge, UK.
[12
]
Department of Bioengineering and Therapeutic Sciences, University of California San
Francisco, San Francisco, CA, USA.
[13
]
The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California
San Francisco, San Francisco, CA, USA.
[14
]
Center for Computational Biology and Bioinformatics, Department of Medicine, University
of California San Diego, San Diego, CA, USA.
[15
]
Department of Cell and Tissue Biology, University of California San Francisco, San
Francisco, CA, USA.
[16
]
Department of Pharmacology, University of North Carolina at Chapel Hill School of
Medicine, Chapel Hill, NC, USA.
[17
]
Biophysics Graduate Program, University of California San Francisco, San Francisco,
CA, USA.
[18
]
Department of Biochemistry and Biophysics, University of California San Francisco,
San Francisco, CA, USA.
[19
]
Zoic Labs, Culver City, CA, USA.
[20
]
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco,
San Francisco, CA, USA.
[21
]
Department of Urology, University of California San Francisco, San Francisco, CA,
USA.
[22
]
Cardiovascular Research Institute, University of California San Francisco, San Francisco,
CA, USA.
[23
]
Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
[24
]
George William Hooper Foundation, Department of Microbiology and Immunology, University
of California San Francisco, San Francisco, CA, USA.
[25
]
Medical Scientist Training Program, University of California San Francisco, San Francisco,
CA, USA.
[26
]
Virus and Immunity Unit, Institut Pasteur, Paris, France.
[27
]
Department of Medicine, University of California San Francisco, San Francisco, CA,
USA.
[28
]
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
[29
]
Department of Psychiatry, University of California San Francisco, San Francisco, CA,
USA.
[30
]
Buck Institute for Research on Aging, Novato, CA, USA.
[31
]
Direction Scientifique, Institut Pasteur, Paris, France.
[32
]
Division of Genetics, Department of Medicine, University of California San Diego,
San Diego, CA, USA.
[33
]
Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
marco.vignuzzi@pasteur.fr.
[34
]
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY,
USA. Adolfo.Garcia-Sastre@mssm.edu.
[35
]
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount
Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.
[36
]
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine
at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.
[37
]
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY,
USA. Adolfo.Garcia-Sastre@mssm.edu.
[38
]
QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.
[39
]
Quantitative Biosciences Institute (QBI), University of California San Francisco,
San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.
[40
]
Department of Cellular and Molecular Pharmacology, University of California San Francisco,
San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.
[41
]
Howard Hughes Medical Institute, University of California San Francisco, San Francisco,
CA, USA. Kevan.Shokat@ucsf.edu.
[42
]
QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. shoichet@cgl.ucsf.edu.
[43
]
Quantitative Biosciences Institute (QBI), University of California San Francisco,
San Francisco, CA, USA. shoichet@cgl.ucsf.edu.
[44
]
Department of Pharmaceutical Chemistry, University of California San Francisco, San
Francisco, CA, USA. shoichet@cgl.ucsf.edu.
[45
]
QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. nevan.krogan@ucsf.edu.
[46
]
Quantitative Biosciences Institute (QBI), University of California San Francisco,
San Francisco, CA, USA. nevan.krogan@ucsf.edu.
[47
]
J. David Gladstone Institutes, San Francisco, CA, USA. nevan.krogan@ucsf.edu.
[48
]
Department of Cellular and Molecular Pharmacology, University of California San Francisco,
San Francisco, CA, USA. nevan.krogan@ucsf.edu.
[49
]
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY,
USA. nevan.krogan@ucsf.edu.
